Limits...
Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion

View Article: PubMed Central - PubMed

ABSTRACT

The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).

Twenty-four patients with non–small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m2) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume. Pharmacokinetic (PK) profile and urinary excretion rate of paclitaxel were analyzed with serum vascular endothelial growth factor (VEGF) level, and adverse events were examined as well.

The combination therapy reduced the MPE level with a successful rate of 29% and a survival rate of 25% over the single paclitaxel treatment in the study cohort (both P < 0.05). PKs for the combined treatment displayed a rapid distribution of the anticancer drug paclitaxel with an obvious increase in its elimination half-life in the pleural fluid (both P < 0.01). Mean residence time of paclitaxel increased in the presence of Avastin (P < 0.01). Serum VEGF levels significantly reduced in the Avastin-treated patients as compared to the paclitaxel-treated ones (P < 0.01). The urinary excretion rate was similar in the study cohort. Incidence of adverse events for the 2 treatment approaches was similar in the patients.

Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues.

No MeSH data available.


Related in: MedlinePlus

Urinary excretion rate of paclitaxel. A 24-hour urinary excretion rate for the drug paclitaxel was performed in presence (n = 14) and absence (n = 10) of Avastin. The results regarding the excretion rate of the drug (black) and the drug remained in body (white) were expressed as a percentage of the drug eliminated from the study cohort. A χ2 test showed a P value >0.05 between these 2 treatment approaches.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5134869&req=5

Figure 5: Urinary excretion rate of paclitaxel. A 24-hour urinary excretion rate for the drug paclitaxel was performed in presence (n = 14) and absence (n = 10) of Avastin. The results regarding the excretion rate of the drug (black) and the drug remained in body (white) were expressed as a percentage of the drug eliminated from the study cohort. A χ2 test showed a P value >0.05 between these 2 treatment approaches.

Mentions: Urinary excretion rates for the paclitaxel treatment were examined in presence (n = 14) and absence (n = 10) of Avastin, and the results are shown in Fig. 5. An excretion test was performed on 24-hour urine collections, and a similar change in the urinary excretion rate was detected in the collected specimens from the patients treated with and without Avastin. The average values (%) for the excretion rates of the drug were shown as 22% and 15% in the paclitaxel- and the paclitaxel/Avastin-treated patients, respectively. In contrast, there was no significant difference in the excretion rates between these 2 treatment approaches.


Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
Urinary excretion rate of paclitaxel. A 24-hour urinary excretion rate for the drug paclitaxel was performed in presence (n = 14) and absence (n = 10) of Avastin. The results regarding the excretion rate of the drug (black) and the drug remained in body (white) were expressed as a percentage of the drug eliminated from the study cohort. A χ2 test showed a P value >0.05 between these 2 treatment approaches.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5134869&req=5

Figure 5: Urinary excretion rate of paclitaxel. A 24-hour urinary excretion rate for the drug paclitaxel was performed in presence (n = 14) and absence (n = 10) of Avastin. The results regarding the excretion rate of the drug (black) and the drug remained in body (white) were expressed as a percentage of the drug eliminated from the study cohort. A χ2 test showed a P value >0.05 between these 2 treatment approaches.
Mentions: Urinary excretion rates for the paclitaxel treatment were examined in presence (n = 14) and absence (n = 10) of Avastin, and the results are shown in Fig. 5. An excretion test was performed on 24-hour urine collections, and a similar change in the urinary excretion rate was detected in the collected specimens from the patients treated with and without Avastin. The average values (%) for the excretion rates of the drug were shown as 22% and 15% in the paclitaxel- and the paclitaxel/Avastin-treated patients, respectively. In contrast, there was no significant difference in the excretion rates between these 2 treatment approaches.

View Article: PubMed Central - PubMed

ABSTRACT

The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).

Twenty-four patients with non–small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m2) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume. Pharmacokinetic (PK) profile and urinary excretion rate of paclitaxel were analyzed with serum vascular endothelial growth factor (VEGF) level, and adverse events were examined as well.

The combination therapy reduced the MPE level with a successful rate of 29% and a survival rate of 25% over the single paclitaxel treatment in the study cohort (both P < 0.05). PKs for the combined treatment displayed a rapid distribution of the anticancer drug paclitaxel with an obvious increase in its elimination half-life in the pleural fluid (both P < 0.01). Mean residence time of paclitaxel increased in the presence of Avastin (P < 0.01). Serum VEGF levels significantly reduced in the Avastin-treated patients as compared to the paclitaxel-treated ones (P < 0.01). The urinary excretion rate was similar in the study cohort. Incidence of adverse events for the 2 treatment approaches was similar in the patients.

Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues.

No MeSH data available.


Related in: MedlinePlus